<DOC>
	<DOCNO>NCT00951405</DOCNO>
	<brief_summary>This trial conduct Asia , Europe , Japan North America . The aim clinical trial investigate safety efficacy prophylactic treatment option long act coagulation factor VII ( LA-rFVIIa ) haemophilia patient inhibitor .</brief_summary>
	<brief_title>Safety Efficacy 3 Different Doses Long Acting Factor VII Haemophilia A B Patients With Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male haemophilia A B patient inhibitor Willing undergo bleed preventive regimen 3 month ' duration total trial length approximately 8 month Historical ongoing high titre inhibitor ( equal 5 BU ) base either medical record , laboratory report review , patient and/or care provider interview At least 2 bleed episode require bypass haemostaticdrugbased treatment within last month 12 bleeding episode within last 6 month prior observation period Body weight 30 100 kg ( inclusive ) Body Mass Index ( BMI ) 30 kg/m2 Immune tolerance induction therapy within last month prior enter observation phase period Known active pseudo tumour Platelet count le 50,000 platelets/microL ( base local laboratory value screen visit ) Congenital acquire coagulation disorder haemophilia A B Surgery within one month prior observation period . Catheter , stent dental extraction count surgery , i.e . exclude patient . Port insertion classify surgery Scheduled major and/or orthopaedic surgery , trial period Follow visit . Catheter , stent dental extraction count surgery exclude patient . Port insertion classify surgery Advanced atherosclerotic disease ( i.e . know history ischemic heart disease , ischemic stroke ) Any clinical sign know history thromboembolic event incl . know deep vein thrombosis ( DVT ) Known clinically suspect allergy activate recombinant human factor VII ( NovoSeven®/NovoSeven RT®/Niastase® ) Prothrombin Time ( PT ) prolongation ( 30 % normal limit , 5 second compare control International Normalised Range ( INR ) 1.7 define local laboratory range screen visit Severe liver disease ( ALAT 4 time upper limit normal reference range ) ( defined local laboratory range ) within year enrolment screen Clinical sign renal dysfunction ( dialysis ) and/or creatinine level equal 20 % upper normal limit ( accord local laboratory range screen visit ) Dosing investigational drug within last 30 day prior present trial Any disease condition , accord investigator 's judgement , could imply potential hazard subject , interfere trial participation trial outcome HIV positive patient either low CD4+ lymphocyte count ( 200/microL less base medical record within 6 month laboratory screen screen visit ) , HCVPCR positive ( base medical record ) , low CD4+ lymphocyte count ( 200/microL less ) HCVPCR positive . If HCVPCR test locally available , HIV positive patient HCV antibody positive include Need use PEGylated pharmaceutical drug trial period</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>